Zdrowie i gospodarka · 16/03/2020

FDA Announces Final Guidance for Rare Diseases with Single Enzyme Defects

The FDA has released a final guidance document providing evidence of effectiveness for replacement or corrective therapies for slowly progressive, low-prevalence rare diseases caused by single enzyme defects, and offers guidance for the industry on how to demonstrate the effectiveness of these treatments.